Log In
Print
BCIQ
Print
Print this Print this
 

BHQ880

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHuman HuCAL neutralizing antibody against Dickkopf homolog 1 (DKK1)
Molecular Target Dickkopf homolog 1 (DKK1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat tumor induced osteolytic bone disease in multiple myeloma (MM) patients
Regulatory Designation

Partner

MorphoSys AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today